In severe asthma with an eosinophilic phenotype, depemokimab improved exacerbations, but not quality of life, at 52 wk. McDonald CF. Ann Intern Med 2025 Jan 7. doi: 10.7326/ANNALS-24-03437.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

McDonald CF. In severe asthma with an eosinophilic phenotype, depemokimab improved exacerbations, but not quality of life, at 52 wk. Ann Intern Med 2025 Jan 7. doi: 10.7326/ANNALS-24-03437.
PMID: 39761576